These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122. Bladder cancer. Borden LS; Clark PE; Hall MC Curr Opin Oncol; 2003 May; 15(3):227-33. PubMed ID: 12778017 [TBL] [Abstract][Full Text] [Related]
123. Immunotherapy in the Treatment of Localized Genitourinary Cancers. Necchi A; Faltas BM; Slovin SF; Meeks JJ; Pal SK; Schwartz LH; Huang RSP; Li R; Manley B; Chahoud J; Ross JS; Spiess PE JAMA Oncol; 2023 Oct; 9(10):1447-1454. PubMed ID: 37561425 [TBL] [Abstract][Full Text] [Related]
124. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Rey-Cárdenas M; Guerrero-Ramos F; Gómez de Liaño Lista A; Carretero-González A; Bote H; Herrera-Juárez M; Carril-Ajuria L; Martín-Soberón M; Sepulveda JM; Billalabeitia EG; Castellano D; de Velasco G Cancer Treat Rev; 2021 Feb; 93():102142. PubMed ID: 33453566 [TBL] [Abstract][Full Text] [Related]
128. Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Deuker M; Martin T; Stolzenbach F; Rosiello G; Collà Ruvolo C; Nocera L; Tian Z; Becker A; Kluth L; Roos FC; Tilki D; Shariat SF; Black PC; Kassouf W; Saad F; Chun F; Karakiewicz PI Clin Genitourin Cancer; 2021 Feb; 19(1):60-68.e1. PubMed ID: 32782133 [TBL] [Abstract][Full Text] [Related]
129. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. Brown AL; Zietman AL; Shipley WU; Kaufman DS Hematol Oncol Clin North Am; 2001 Apr; 15(2):345-58, vii. PubMed ID: 11370497 [TBL] [Abstract][Full Text] [Related]
130. Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. Mir MC; Campi R; Loriot Y; Puente J; Giannarini G; Necchi A; Rouprêt M; Eur Urol Oncol; 2022 Dec; 5(6):726-731. PubMed ID: 33967013 [TBL] [Abstract][Full Text] [Related]
137. Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review. Koukourakis G; Kouloulias V; Zacharias G; Sotiropoulou-Lontou A; Koukourakis M Clin Transl Oncol; 2011 May; 13(5):315-21. PubMed ID: 21596659 [TBL] [Abstract][Full Text] [Related]
138. New immunotherapy treatments in non-muscle invasive bladder cancer. Califano G; Ouzaid I; Verze P; Stivalet N; Hermieu JF; Xylinas E Arch Esp Urol; 2020 Dec; 73(10):945-953. PubMed ID: 33269713 [TBL] [Abstract][Full Text] [Related]
139. Smoking and bladder cancer: review of the recent literature. Mori K; Mostafaei H; Abufaraj M; Yang L; Egawa S; Shariat SF Curr Opin Urol; 2020 Sep; 30(5):720-725. PubMed ID: 32701723 [TBL] [Abstract][Full Text] [Related]
140. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). González Del Alba A; De Velasco G; Lainez N; Maroto P; Morales-Barrera R; Muñoz-Langa J; Pérez-Valderrama B; Basterretxea L; Caballero C; Vazquez S Clin Transl Oncol; 2019 Jan; 21(1):64-74. PubMed ID: 30565086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]